Akebia Therapeutics, Inc.
NASDAQ: AKBA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Butler
- Employees
- 181
- Headquarters
- Cambridge, United States
- IPO year
- 2014
- Market cap
- $284.4M
- Website
- https://www.akebia.com
Loading AKBA…
Loading profile data…Frequently asked questions about AKBA
What does Akebia Therapeutics, Inc. (AKBA) do?
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose i...
Where does AKBA trade?
Akebia Therapeutics, Inc. (AKBA) trades on the NASDAQ Global Market.
What sector is AKBA in?
Akebia Therapeutics, Inc. (AKBA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Akebia Therapeutics, Inc.?
John Butler is the chief executive officer of Akebia Therapeutics, Inc. (AKBA).
Where is Akebia Therapeutics, Inc. headquartered?
Akebia Therapeutics, Inc. is headquartered in United States.
Does AKBA pay a dividend?
Akebia Therapeutics, Inc. (AKBA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AKBA go public?
Akebia Therapeutics, Inc. (AKBA) completed its initial public offering in 2014.